Related references
Note: Only part of the references are listed.Significant Risk of Graft-versus-Host Disease with Exposure to Checkpoint Inhibitors before and after Allogeneic Transplantation
Awais Ijaz et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation
Cristina Toffalori et al.
NATURE MEDICINE (2019)
Bone marrow central memory and memory stem T-cell exhaustion in AML patients relapsing after HSCT
Maddalena Noviello et al.
NATURE COMMUNICATIONS (2019)
Chimeric Antigen Receptor (CAR) T Cell Therapy in Acute Myeloid Leukemia (AML)
Susanne Hofmann et al.
JOURNAL OF CLINICAL MEDICINE (2019)
Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML
A. E. Perl et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation in acute leukaemia - a matched pair analysis by the Acute Leukaemia Working Party of EBMT
Christoph Schmid et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
An IL-15 Superagonist, ALT-803, Enhances Antibody-Dependent Cell-Mediated Cytotoxicity Elicited by the Monoclonal Antibody NEO-201 Against Human Carcinoma Cells
Massimo Fantini et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2019)
Combination Lenalidomide and Azacitidine: A Novel Salvage Therapy in Patients Who Relapse After Allogeneic Stem-Cell Transplantation for Acute Myeloid Leukemia
Charles Craddock et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Reversal of T Cell Exhaustion by the First Donor Lymphocyte Infusion Is Associated with the Persistently Effective Antileukemic Responses in Patients with Relapsed AML after Allo-HSCT
Long Liu et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2018)
Early Post-Transplant Minimal Residual Disease Assessment Improves Risk Stratification in Acute Myeloid Leukemia
Mithun Vinod Shah et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2018)
CC-486 Maintenance after Stem Cell Transplantation in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes
Marcos de Lima et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2018)
Relapse and Survival After Transplantation for Complex Karyotype Acute Myeloid Leukemia: A Report From the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation and The University of Texas MD Anderson Cancer Center
Stefan O. Ciurea et al.
CANCER (2018)
Anti-leukemic effects of all-trans retinoic acid in combination with Daratumumab in acute myeloid leukemia
Nathaniel J. Buteyn et al.
INTERNATIONAL IMMUNOLOGY (2018)
CAR-T cells targeting CLL-1 as an approach to treat acute myeloid leukemia
Jinghua Wang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
CAR T-cells targeting FLT3 have potent activity against FLT3(-)ITD(+) AML and act synergistically with the FLT3-inhibitor crenolanib
Hardikkumar Jetani et al.
LEUKEMIA (2018)
Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes
Naval Daver et al.
LEUKEMIA (2018)
Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells
Nimitha R. Mathew et al.
NATURE MEDICINE (2018)
Association of Second Allogeneic Hematopoietic Cell Transplant vs Donor Lymphocyte Infusion With Overall Survival in Patients With Acute Myeloid Leukemia Relapse
Mohamed A. Kharfan-Dabaja et al.
JAMA ONCOLOGY (2018)
Therapeutic Antibodies for Myeloid Neoplasms-Current Developments and Future Directions
Christian M. Schurch
FRONTIERS IN ONCOLOGY (2018)
Check-Point Inhibitors before and after Allogeneic Hematopoietic Stem Cell Transplant: The Double-Edge Sword
Betul Oran et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2018)
Immune Escape of Relapsed AML Cells after Allogeneic Transplantation
M. J. Christopher et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells
Regina Jitschin et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
A Phase I/Ib Study of Nivolumab for Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation (alloHCT)
Matthew S. Davids et al.
BLOOD (2018)
PD-L1 blockade enhances anti-tumor efficacy of NK cells
Jeremiah L. Oyer et al.
ONCOIMMUNOLOGY (2018)
Maintenance with 5-Azacytidine for Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients
Betul Oran et al.
BLOOD (2018)
Donor lymphocyte infusions in AML and MDS: Enhancing the graft-versus-leukemia effect
Guillermo Orti et al.
EXPERIMENTAL HEMATOLOGY (2017)
Recent developments in immunotherapy of acute myeloid leukemia
Felix S. Lichtenegger et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Phase I/II study of the deacetylase inhibitor panobinostat after allogeneic stem cell transplantation in patients with high-risk MDS or AML (PANOBEST trial)
G. Bug et al.
LEUKEMIA (2017)
FLT3 Inhibitors in Acute Myeloid Leukemia: Current Status and Future Directions
Maria Larrosa-Garcia et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Acute myeloid leukemia targets for bispecific antibodies
S. S. Hoseini et al.
BLOOD CANCER JOURNAL (2017)
Epigenetic modifiers upregulate MHC II and impede ovarian cancer tumor growth
Taylor B. Turner et al.
ONCOTARGET (2017)
The More, The Better: Do the Right Thing For natural Killer immunotherapy in Acute Myeloid Leukemia
Sarah Parisi et al.
FRONTIERS IN IMMUNOLOGY (2017)
Major Histocompatibility Mismatch and Donor Choice for Second Allogeneic Bone Marrow Transplantation
Philip H. Imus et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2017)
CD25 Blockade Delays Regulatory T Cell Reconstitution and Does Not Prevent Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation
Frederick L. Locke et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2017)
Targeting CD123 in acute myeloid leukemia using a T-cell-directed dual-affinity retargeting platform
Muneera Al-Hussaini et al.
BLOOD (2016)
Long-term results of adjuvant donor lymphocyte transfusion in AML after allogeneic stem cell transplantation
Z. Jedlickova et al.
BONE MARROW TRANSPLANTATION (2016)
Phase II Study of Haploidentical Natural Killer Cell Infusion for Treatment of Relapsed or Persistent Myeloid Malignancies Following Allogeneic Hematopoietic Cell Transplantation
Brian C. Shaffer et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2016)
Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial
Dean A. Lee et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2016)
Lymphodepleting chemotherapy with donor lymphocyte infusion post-allogeneic HCT for hematological malignancies is associated with severe, but therapy-responsive aGvHD
F. He et al.
BONE MARROW TRANSPLANTATION (2016)
A phase I study of CD25/regulatory T-cell-depleted donor lymphocyte infusion for relapse after allogeneic stem cell transplantation
Sarah Nikiforow et al.
HAEMATOLOGICA (2016)
Ipilimumab for Patients with Relapse after Allogeneic Transplantation
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Redirecting Specificity of T cells Using the Sleeping Beauty System to Express Chimeric Antigen Receptors by Mix-and-Matching of VL and VH Domains Targeting CD123+ Tumors
Radhika Thokala et al.
PLOS ONE (2016)
Histone deacetylase inhibitors as immunomodulators in cancer therapeutics
Li Shen et al.
EPIGENOMICS (2016)
A phase I study of CD25/regulatory T-cell-depleted donor lymphocyte infusion for relapse after allogeneic stem cell transplantation
Sarah Nikiforow et al.
HAEMATOLOGICA (2016)
Prospective Phase II Study of Prophylactic Azacitidine and Donor Lymphocyte Infusions Following Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome
Thierry Guillaume et al.
BLOOD (2016)
Mixed T Lymphocyte Chimerism after Allogeneic Hematopoietic Transplantation Is Predictive for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes
Hans C. Lee et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2015)
Chimerism-Based Pre-Emptive Immunotherapy with Fast Withdrawal of Immunosuppression and Donor Lymphocyte Infusions after Allogeneic Stem Cell Transplantation for Pediatric Hematologic Malignancies
Biljana Horn et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2015)
Immune checkpoint blockade in hematologic malignancies
Philippe Armand
BLOOD (2015)
Treatment of CD33-directed Chimeric Antigen Receptor-modified T Cells in One Patient With Relapsed and Refractory Acute Myeloid Leukemia
Quan-shun Wang et al.
MOLECULAR THERAPY (2015)
Targeting Interleukin-2 to the Bone Marrow Stroma for Therapy of Acute Myeloid Leukemia Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation
Christoph Schliemann et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Effects of T-Cell Depletion on Allogeneic Hematopoietic Stem Cell Transplantation Outcomes in AML Patients
Gabriela Soriano Hobbs et al.
JOURNAL OF CLINICAL MEDICINE (2015)
Post-transplant maintenance therapy with azacitidine and gemtuzumab ozogamicin for high-risk acute myeloid leukaemia
Gaku Oshikawa et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Comparison of minimal residual disease as outcome predictor for AML patients in first complete remission undergoing myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantation
R. B. Walter et al.
LEUKEMIA (2015)
Comparative therapeutic value of post-remission approaches in patients with acute myeloid leukemia aged 40-60 years
J. J. Cornelissen et al.
LEUKEMIA (2015)
A Phase 1 study of the safety, pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed, refractory or high-risk acute myeloid leukemia
Simon Z. He et al.
LEUKEMIA & LYMPHOMA (2015)
Prospective Study of Peri-Transplant Use of Sorafenib As Remission Maintenance for FLT3-ITD Patients Undergoing Allogeneic Transplantation
Keith W. Pratz et al.
BLOOD (2015)
Phase I Trial of Maintenance Sorafenib after Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Internal Tandem Duplication Acute Myeloid Leukemia
Yi-Bin Chen et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2014)
CTLA-4 Is Expressed by Activated Mouse NK Cells and Inhibits NK Cell IFN-γ Production in Response to Mature Dendritic Cells
Ana Stojanovic et al.
JOURNAL OF IMMUNOLOGY (2014)
BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies
J. M. Bogenberger et al.
LEUKEMIA (2014)
Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders
Katrina J. Falkenberg et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
5-Azacytidine treatment sensitizes tumor cells to T-cell mediated cytotoxicity and modulates NK cells in patients with myeloid malignancies
A. O. Gang et al.
BLOOD CANCER JOURNAL (2014)
Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia
A. Ehninger et al.
BLOOD CANCER JOURNAL (2014)
Outcome of Donor Lymphocyte Infusion after T Cell-depleted Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndromes
Pramila Krishnamurthy et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2013)
Donor Lymphocyte Infusion for Relapsed Hematological Malignancies after Allogeneic Hematopoietic Cell Transplantation: Prognostic Relevance of the Initial CD3+ T Cell Dose
Merav Bar et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2013)
Pre-emptive immunotherapy with purified natural killer cells after haploidentical SCT: a prospective phase II study in two centers
M. Stern et al.
BONE MARROW TRANSPLANTATION (2013)
An Intact Immune System Is Required for the Anticancer Activities of Histone Deacetylase Inhibitors
Alison C. West et al.
CANCER RESEARCH (2013)
Second Allograft for Hematologic Relapse of Acute Leukemia After First Allogeneic Stem-Cell Transplantation From Related and Unrelated Donors: The Role of Donor Change
Maximilian Christopeit et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Antibody-Based Delivery of Interleukin-2 to Neovasculature Has Potent Activity Against Acute Myeloid Leukemia
Katrin L. Gutbrodt et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Successful Remission Rates and Survival after Lymphodepleting Chemotherapy and Donor Lymphocyte Infusion for Relapsed Hematologic Malignancies Postallogeneic Hematopoietic Cell Transplantation
Erica D. Warlick et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2012)
A disease risk index for patients undergoing allogeneic stem cell transplantation
Philippe Armand et al.
BLOOD (2012)
Impact of FLT3 Internal Tandem Duplication on the Outcome of Related and Unrelated Hematopoietic Transplantation for Adult Acute Myeloid Leukemia in First Remission: A Retrospective Analysis
Salut Brunet et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial
U. Platzbecker et al.
LEUKEMIA (2012)
High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses
S. K. Metzelder et al.
LEUKEMIA (2012)
Immunomodulatory effect of 5-azacytidine (5-azaC): potential role in the transplantation setting
Luis I. Sanchez-Abarca et al.
BLOOD (2010)
In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia
Jaebok Choi et al.
BLOOD (2010)
Gemtuzumab Ozogamicin Therapy for Isolated Extramedullary AML Relapse after Allogeneic Hematopoietic Stem-Cell Transplantation
Toshihiko Ando et al.
TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE (2010)
Loss of Mismatched HLA in Leukemia after Stem-Cell Transplantation.
Luca Vago et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Simultaneously targeting CD45 significantly increases cytotoxicity of the anti-CD33 immunoconjugate, gemtuzumab ozogamicin, against acute myeloid leukemia (AML) cells and improves survival of mice bearing human AML xenografts
Roland B. Walter et al.
BLOOD (2008)
Donor lymphocyte infusion in the treatment of first Hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia:: A retrospective risk factors analysis and comparison with other strategies by the EBMT acute leukemia working party
Christoph Schmid et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Gemtuzumab therapy for isolated extramedullary AML relapse following allogeneic stem-cell transplant
Taofeek Owonikoko et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2007)
Licensing of natural killer cells by host major histocompatibility complex class I molecules
S Kim et al.
NATURE (2005)
Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer
JS Miller et al.
BLOOD (2005)
Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation
M Wadleigh et al.
BLOOD (2003)
CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation
M Edinger et al.
NATURE MEDICINE (2003)
The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation
DI Marks et al.
BLOOD (2002)
Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose
C Guglielmi et al.
BLOOD (2002)
Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants
L Ruggeri et al.
SCIENCE (2002)
Individually adjusted prophylactic donor lymphocyte infusions after CD34-selected allogeneic peripheral blood stem cell transplantation
C Ferrá et al.
BONE MARROW TRANSPLANTATION (2001)
The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials
PD Kottaridis et al.
BLOOD (2001)
Differential use of Fas ligand and perforin cytotoxic pathways by donor T cells in graft-versus-host disease and graft-versus-leukemia effect
C Schmaltz et al.
BLOOD (2001)
The number of donor CD3+ cells is the most important factor for graft failure after allogeneic transplantation of CD34+ selected cells from peripheral blood from HLA-identical siblings
A Urbano-Ispizua et al.
BLOOD (2001)
The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells
CT Jordan et al.
LEUKEMIA (2000)
Share Paper
